Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 28 Oct 2016

TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies in immuno-oncology: TCR and checkpoint inhibitors. Adaptimmune is an immuno-oncology billion-euro Biotech from the British Golden Triangle. Despite some trouble with the FDA recently, the company continues to forge ahead with its promising TCR technology. Now, […]

October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 10 26 at 1.52.35 PM 1 e1477644606273

News and Trends 28 Oct 2016

Meet Spain’s Gold BIOMEDAList in Celiac Disease

This week we’re heading South back to my hometown, Sevilla! Even well into October, the skies are clear and the sun is shining while we drop by Biomedal, this week’s Biotech. City: Sevilla, Spain Founded: 2000 Employees: 31 Financial data: €2.5M in sales with an impressive 60% growth in the last year Mission: The company has three […]

October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Oct 2016

€36M Fundraising to Sequence the Genome of Ireland

Genomics Medicine Ireland (GMI) has raised €36M ($40M) in series A to sequence the genome of the Irish and use the info for the development of new drugs and diagnostics. Genomics Medicine Ireland (GMI) is committed to revolutionizing health care with whole-genome sequencing. The company just raised €36M ($40M) in Series A that will be used to […]

October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Oct 2016

Boehringer enters the Biosimilar War against Blockbuster Humira

Boehringer Ingelheim just announced positive Phase III results for its Humira biosimilar. The company is joining many others in the fights to take a bite of the huge market that will be open for access when patents expire later this year. AbbVie’s Humira (adalimumab) is the best selling biological, with a jaw-dropping €13B ($14B) in […]

October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Oct 2016

Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

Nordic Nanovector is collaborating with Heidelberg Pharma to access the promising antibody-drug conjugate (ADC) technology. However, can it really take on the strong competition? Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat Non-Hodgkin Lymphoma (NHL) and other blood cancers. Today, the company has announced a collaboration with Wilex’ subsidiary Heidelberg Pharma to incorporate antibody-drug conjugates (ADCs) […]

October 26, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Oct 2016

The First Peanut Allergy Therapy might soon hit the Shelves

DBV Technologies announced outstanding Phase IIb results for Viaskin Peanut, which could be the first-ever commercial peanut allergy therapy in the near future. However, competition is stiff. DBV Technologies, the first French Biotech to enter the NASDAQ, aims to be the first to attain approval for a food allergy therapy. The company’s lead pipeline candidate […]

October 25, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 10 25 at 3.57.12 PM e1477403929643

News and Trends 25 Oct 2016

This Diagnostic Tool beats the Standard for Respiratory Infection Tests

Curetis is drastically reducing the time required to test for severe infectious diseases. The newest incorporation is expected early next year and could soon substitute the hospital standards. Curetis is a German biotech that commercializes diagnostic technologies for infectious diseases. After a very successful IPO last year, the company is advancing its Unyvero platform for fast diagnostics. The […]

October 25, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Oct 2016

Meet the Cyborg Bacteria that Culture Themselves

What if you could program your bacteria to grow in any pattern you fancy? Researchers from ETH Zurich can, and this is huge news for the Biotech Industry! Scientists from ETH Zurich have developed a fully automated system that can precisely control bacterial growth using light. What’s more, unlike other prototypes, this system can adjust to any […]

October 25, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Oct 2016

A €103M Target to Reduce Drug Dosage with a Slow-Release Tech

Ascendis aims to raise €103M ($112M) for Phase III trials in Growth Hormone Deficiency (GHD) that offer children a weekly alternative to daily injections. After its IPO on NASDAQ last year, the Danish Ascendis is making an underwritten public offering in the US that aims to raise €103M ($112M) to advance its TransCon pipeline. The funds will be directed to […]

October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Oct 2016

Here comes the First-ever Combination Therapy for Multiple Sclerosis

Actelion is overcoming the upcoming expiration of one of its most profitable patents and it’s using its strong position to make the leap into the crowded market of multiple sclerosis with the first-ever combination therapy. Actelion is one of the top billion-euro Biotechs in Europe and a leader in pulmonary arterial hypertension (PAH). Although the patent for […]

October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

The Growing Lab Mycelia ©Officina Corpuscoli Maurizio Montalti pure mycelium pattern2 e1477066281946

News and Trends 22 Oct 2016

Meet the Bioartist that wants to Replace all your Furniture with… Fungi!

Can you imagine a future where everything in your daily life is made out of fungi..? It’s actually not such a stretch idea: this bioartist is showing the world all these microorganisms can do. Maurizio Montalti is an artist that uses fungi to build his own furniture and homeware. In 2010, he founded Officina Corpuscoli in Amsterdam […]

October 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 10 21 at 12.29.43 PM e1477045913351

News and Trends 21 Oct 2016

New Partnership comes to the Rescue in Neurological Diseases

Developing effective treatments for neurological diseases is a big challenge in medicine. But here come UCB and Evotec with a new partnership that could help those suffering from epilepsy and Parkinson’s. UCB is a Biotech from Brussels that focuses on neurological and immune diseases. The company has multiple products on the market, including an antibody drug for arthritis and […]

October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clara Rodríguez Fernández

About

Articles by Clara Rodríguez Fernández

TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

Meet Spain’s Gold BIOMEDAList in Celiac Disease

€36M Fundraising to Sequence the Genome of Ireland

Boehringer enters the Biosimilar War against Blockbuster Humira

Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

The First Peanut Allergy Therapy might soon hit the Shelves

This Diagnostic Tool beats the Standard for Respiratory Infection Tests

Meet the Cyborg Bacteria that Culture Themselves

A €103M Target to Reduce Drug Dosage with a Slow-Release Tech

Here comes the First-ever Combination Therapy for Multiple Sclerosis

Meet the Bioartist that wants to Replace all your Furniture with… Fungi!

New Partnership comes to the Rescue in Neurological Diseases

Subscribe to our newsletter to get the latest biotech news!